Form 4: Citius Pharmaceuticals Vice Chairman Myron Z. Holubiak Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Myron Z. Holubiak, Vice Chairman of Citius Pharmaceuticals, files Form 4 detailing warrant amendment and holdings of common stock and stock options.
Summary
- Myron Z. Holubiak, Vice Chairman of Citius Pharmaceuticals, filed a Form 4 with the SEC.
- The filing reports changes in beneficial ownership of Citius Pharmaceuticals securities.
- The reported transactions include an amendment of an outstanding warrant, extending the termination date from April 5, 2024, to April 5, 2025.
- This amendment resulted in the cancellation of the old warrant and the grant of a replacement warrant.
- Holubiak directly owns 1,992,243 shares of common stock.
- He also holds various stock options and warrants to purchase common stock at different exercise prices and expiration dates.
- Some stock options are held directly, while others are held indirectly through his daughter, for which he disclaims beneficial ownership.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports transactions and holdings.
Positives
- The extension of the warrant's expiration date provides Holubiak with more time to potentially exercise the warrant.
Industry Context
Form 4 filings are a routine part of regulatory compliance for company insiders and provide transparency into their transactions in the company's securities. This filing is specific to an individual officer and doesn't necessarily reflect broader industry trends.
Stakeholder Impact
- Shareholders may be interested in the insider's holdings and transactions as an indicator of management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 12/31/2016 | Options for 26,667 shares at $8.10 vested in full. |
| 10/08/2029 | Expiration date for options to purchase 175,000 shares at $0.67. |
| 10/06/2030 | Expiration date for options to purchase 200,000 shares at $1.01. |
| 07/22/2031 | Expiration date for options to purchase 300,000 shares at $2.00. |
| 10/11/2031 | Expiration date for options to purchase 650,000 shares at $2.04. |
| 10/04/2032 | Expiration date for options to purchase 400,000 shares at $1.25. |
| 10/10/2033 | Expiration date for options to purchase 400,000 shares at $0.70. |
| 09/13/2020 | Options for 40,000 shares at $3.45 vested in full. |
| 09/04/2021 | Options for 150,000 shares at $1.62 vested in full. |
| 07/22/2021 | Options for 300,000 shares at $2.00 were granted. |
| 10/11/2021 | Options for 650,000 shares at $2.04 were granted. |
| 10/04/2022 | Options for 400,000 shares at $1.25 were granted. |
| 10/08/2022 | Options for 175,000 shares at $0.67 vested in full. |
| 10/10/2023 | Options for 400,000 shares at $0.70 were granted. |
| 10/06/2023 | Options for 200,000 shares at $1.01 vested in full. |
| 08/14/2024 | Warrant to purchase 784,314 shares at $1.15 expires. |
| 09/27/2024 | Warrant to purchase 558,597 shares at $0.77 expires. |
| 04/03/2024 | Date of earliest transaction; warrant amendment. |
| 04/05/2024 | Date of Form 4 filing; amended warrant expires. |
| 04/05/2025 | Amended warrant expiration date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.